Literature DB >> 12682723

Pharmacogenetics and the future of medical practice.

Klaus Lindpaintner1.   

Abstract

Pharmacogenetics is today widely proclaimed to be about to revolutionize the face of medicine. In a more realistic assessment, the implementation of molecular genetics and biology will continue to provide us, as it has done already, with better ways to diagnose and treat illnesses, but it will do so at a stepwise and evolutionary pace, based on an improved understanding of the nature of disease, allowing more specific treatments, better risk prediction, and the implementation of preventive strategies. As such, future progress in biomedicine will travel the same well-trodden paths of improved differential diagnosis and risk prediction along which it has advanced in the past decades and centuries. Thus, while meaningful biomedical research today by and large depends on the use of the newly developed tools of genetics and genomics and the insights that we gain through them, it is unlikely fundamentally to change the direction of medical progress.

Entities:  

Mesh:

Year:  2003        PMID: 12682723     DOI: 10.1007/s00109-002-0416-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  22 in total

Review 1.  Pharmacogenetics and future drug development and delivery.

Authors:  A D Roses
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

2.  Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.

Authors:  S Tan; I P Hall; J Dewar; E Dow; B Lipworth
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

3.  HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group.

Authors:  I Theodorou; L Meyer; M Magierowska; C Katlama; C Rouzioux
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

4.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

6.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

7.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

8.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.

Authors:  F D Martinez; P E Graves; M Baldini; S Solomon; R Erickson
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

9.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

Authors:  D W McGraw; S L Forbes; L A Kramer; S B Liggett
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

View more
  7 in total

Review 1.  Pharmacogenetics of antihypertensive drug response.

Authors:  Reinhold Kreutz
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 2.  Asthma treatment in the 21st century: what's next?

Authors:  Stephen P Peters
Journal:  Clin Rev Allergy Immunol       Date:  2004-12       Impact factor: 8.667

3.  Racializing drug design: implications of pharmacogenomics for health disparities.

Authors:  Sandra Soo-Jin Lee
Journal:  Am J Public Health       Date:  2005-10-27       Impact factor: 9.308

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

Review 6.  Pharmacogenetics of lipid diseases.

Authors:  Jose M Ordovas
Journal:  Hum Genomics       Date:  2004-01       Impact factor: 4.639

7.  PharmGED: Pharmacogenetic Effect Database.

Authors:  C J Zheng; L Y Han; B Xie; C Y Liew; S Ong; J Cui; H L Zhang; Z Q Tang; S H Gan; L Jiang; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2006-12-06       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.